Perspectives | Apellis Pharmaceuticals, Inc.

Skip to main navigation

Loading...

About Us
Our Science
For Patients
- For Patients
- PNH
- Geographic Atrophy
- C3G
- CAD
- Expanded Access
Careers
- Careers
- Opportunities
Investors & Media
Contact Us
Twitter
LinkedIn

Investors & Media

Home / Investors & Media / Perspectives Perspectives

Perspectives

Seeking Alpha

September 12, 2018

Dosing underway in Apellis Pharma's late-stage program of APL-2 in geographic a…

Healio

September 12, 2018

Apellis begins phase 3 clinical program for geographic atrophy treatment

Retinal Physician

August 31, 2018

SUBSPECIALTY NEWS: Sustained-release drug, 12-week dosing, and more

Boston Business Journal

August 23, 2018

Kentucky biotech Apellis plans major expansion in Mass

Healio, Ocular Surgery News

July 28, 2018

Apellis begins phase 3 clinical program for geographic atrophy program

Healio, Ocular Surgery News

July 24, 2018

Fast track designation granted for Apellis’ geographic atrophy treatment

Endpoints News

July 24, 2018

FDA hands Apellis Pharmaceuticals fast track designation for its advanced dry A…

Modern Retina

July 22, 2018

What APL-2 means for geographic atrophy

Medscape

July 22, 2018

New Geographic Atrophy Treatment Shows Promise

Chief Executive

June 28, 2018

Q&A: Apellis Pharmaceuticals CEO Dr. Cedric Francois

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Print Page Email Alerts RSS Feeds Contact IR

© Apellis Pharmaceuticals 2020. |

Privacy Policy

This website is intended for residents of the U.S.